儿童慢性肾脏病进展风险的现有和新型生物标志物。
Current and Novel Biomarkers of Progression Risk in Children with Chronic Kidney Disease.
机构信息
Department of Pediatrics, Taibah University College of Medicine, Medina, Saudi Arabia,
Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA.
出版信息
Nephron. 2024;148(1):1-10. doi: 10.1159/000530918. Epub 2023 May 15.
BACKGROUND
Due to the complexity of chronic kidney disease (CKD) pathophysiology, biomarkers representing different mechanistic pathways have been targeted for the study and development of novel biomarkers. The discovery of clinically useful CKD biomarkers would allow for the identification of those children at the highest risk of kidney function decline for timely interventions and enrollment in clinical trials.
SUMMARY
Glomerular filtration rate and proteinuria are traditional biomarkers to classify and prognosticate CKD progression in clinical practice but have several limitations. Over the recent decades, novel biomarkers have been identified from blood or urine with metabolomic screening studies, proteomic screening studies, and an improved knowledge of CKD pathophysiology. This review highlights promising biomarkers associated with the progression of CKD that could potentially serve as future prognostic markers in children with CKD.
KEY MESSAGES
Further studies are needed in children with CKD to validate putative biomarkers, particularly candidate proteins and metabolites, for improving clinical management.
背景
由于慢性肾脏病（CKD）病理生理学的复杂性，针对不同机制途径的生物标志物已成为研究和开发新型生物标志物的目标。发现临床上有用的 CKD 生物标志物将有助于识别那些肾功能下降风险最高的儿童，以便及时进行干预并纳入临床试验。
总结
肾小球滤过率和蛋白尿是传统的生物标志物，用于在临床实践中对 CKD 进展进行分类和预后判断，但存在一些局限性。在最近几十年中，通过代谢组学筛选研究、蛋白质组学筛选研究以及对 CKD 病理生理学的深入了解，已经从血液或尿液中鉴定出了新型生物标志物。本综述强调了与 CKD 进展相关的有前途的生物标志物，这些标志物有可能成为儿童 CKD 的未来预后标志物。
关键信息
需要对患有 CKD 的儿童进行进一步的研究，以验证候选生物标志物，特别是候选蛋白和代谢物，从而改善临床管理。
Zotero 插件